Vanguard Capital Management
APLS

Vanguard Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Vanguard Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,768,944
Closed -$192M – 4095
2026
Q1 		$192M Buy
+4,768,944
New +$103M ﹤0.01% 1085

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Capital Management's APLS Position: Q2 2026 in Review

Vanguard Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 4,768,944 shares — an estimated $192M sold.

Vanguard Capital Management first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $192M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Vanguard Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Capital Management sold 4,768,944 Apellis Pharmaceuticals shares in Q2 2026, an estimated $192M.
  • Vanguard Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Capital Management's Apellis Pharmaceuticals position peaked at $192M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.